Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
Top Cited Papers
Open Access
- 15 June 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 99 (12), 4364-4369
- https://doi.org/10.1182/blood.v99.12.4364
Abstract
Recipients of a partially T-cell–depleted (TCD) allogeneic stem cell transplantation (allo-SCT) developing reactivation of Epstein-Barr virus (EBV) with quantified viral DNA levels exceeding 1000 genome equivalents/milliliter (geq/mL) are at high risk for EBV–lymphoproliferative disease (EBV-LPD). We studied whether preemptive therapy with rituximab prevents EBV-LPD, LPD-mortality, and abrogates viral reactivation in high-risk patients. We monitored 49 recipients of a TCD allo-SCT weekly for EBV reactivation by quantitative real-time polymerase chain reaction (PCR). Preemptive therapy by a single infusion of rituximab was given to patients with viral reactivation more than or equal to 1000 geq/mL. Results were compared with an historical control group of patients retrospectively monitored for EBV reactivation at similar intervals. There were 17 prospectively monitored patients who showed EBV reactivation more than or equal to 1000 geq/mL and 15 received preemptive therapy. Median time to preemptive therapy was 113 days (range, 41-202 days) after SCT. There were 14 patients who showed complete response (CR) as characterized by prevention of EBV-LPD and complete clearance of EBV-DNA from plasma, which was achieved after a median number of 8 days (range, 1-46 days). One patient progressed to EBV-LPD despite pre-emptive therapy, but obtained CR after 2 infusions of rituximab and donor lymphocyte infusion. There were 2 patients who had already developed EBV-LPD prior to preemptive rituximab, but obtained CR following 2 rituximab infusions. Comparison of this prospectively followed series to our historical cohort with the same high-risk profile showed a reduction of EBV-LPD incidence (18% ± 9% versus 49% ± 11%, respectively) and a complete abrogation of LPD-mortality (0% versus 26% ± 10%, respectively) (P = .04) at 6 months from EBV-DNA more than or equal to 1000 geq/mL. Frequent quantitative monitoring of EBV reactivation and preemptive therapy by rituximab improves outcome in patients at high risk of EBV-LPD.Keywords
This publication has 31 references indexed in Scilit:
- Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in childrenBritish Journal of Haematology, 2001
- Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patientsBlood, 2001
- Viral Subversion of the Immune SystemAnnual Review of Immunology, 2000
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcomeBone Marrow Transplantation, 1999
- The antiviral prophylaxis of post-transplant lymphoproliferative disorderSpringer Seminars in Immunopathology, 1998
- Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell TransplantationDrugs, 1998
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.The Journal of Experimental Medicine, 1991
- Latent and Replicating Forms of Epstein-Barr Virus DNA in Lymphomas and Lymphoproliferative DiseasesThe Journal of Infectious Diseases, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958